OBWG
SLNO

Onyx Bridge Wealth Group’s Soleno Therapeutics SLNO Stock Holding History

Onyx Bridge Wealth Group’s Portfolio SLNO Stock Details SLNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-1,333
Closed -$4K – 195
2022
Q2 		$4K Buy
+1,333
New +$3.69K ﹤0.01% 165

Other funds holding SLNO

A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return
GPCM
Granite Point Capital Management Boston, Massachusetts $4.9M AUM 38.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WVP
Worth Venture Partners Fort Lee, New Jersey $31.6M AUM 28.5% 1-Year Est. Return
CP
Clayton Partners Berkeley, California $138M AUM 38.58% 1-Year Est. Return
JGC
J. Goldman & Co New York $3.44B AUM 33.8% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Onyx Bridge Wealth Group's SLNO Position: Q3 2022 in Review

Onyx Bridge Wealth Group sold out of Soleno Therapeutics (SLNO) in Q3 2022, closing a stake of 1,333 shares — an estimated $4K sold.

Onyx Bridge Wealth Group first reported a position in SLNO in Q2 2022 and held it in 1 quarter. The position peaked at $4K in Q2 2022. 22 funds tracked by Wall St. Rank hold SLNO as of Q3 2022.

  • Onyx Bridge Wealth Group reported no remaining Soleno Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Onyx Bridge Wealth Group sold 1,333 Soleno Therapeutics shares in Q3 2022, an estimated $4K.
  • Onyx Bridge Wealth Group first reported a position in Soleno Therapeutics in Q2 2022 and held it in 1 quarter.
  • Onyx Bridge Wealth Group's Soleno Therapeutics position peaked at $4K in Q2 2022.
  • 22 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q3 2022.

Based on Onyx Bridge Wealth Group's 13F filing for Q3 2022, filed 13 Oct 2022.